Literature DB >> 18188838

Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.

Arne Schäfer1, Hans-Ulrich Wittchen, Jochen Seufert, Michael R Kraus.   

Abstract

In recent years, research on interferon (IFN)-induced depressive symptoms in antivirally treated patients suffering from chronic hepatitis C (CHC) has considerably intensified. Profound scientific knowledge of this complication is of great relevance with regard to adherence, compliance, and premature therapy discontinuation. Presently, there is considerable variability of both, the frequency and extent of IFN-induced depression reported in different cohorts of patients. The aim of the presented study was to systematically review recent literature of research within this field; and particularly (1) to identify to what extent methodological bias contributed to inconsistent results in different studies, (2) to critically appraise methods and results of studies published so far, and (3) to suggest directions for future work, especially with respect to alternative and improved methodological approaches. The results of this critical review suggest that the variability of findings seem to be largely due to different study populations, treatment regimens, methodological approaches, and sometimes arbitrary or at least poorly defined choice of screening instruments for depression, particularly criteria for clinically relevant depression (cut-off criteria). Study designs and methodological approaches to investigate IFN-alfa-induced depression in patients with CHC have been incoherent. Future research in this field needs agreement on the use of standardized assessment of IFN-induced depression in CHC. Furthermore, objective criteria and guidelines for the treatment of IFN-induced depression in these patients are needed in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18188838      PMCID: PMC6878515          DOI: 10.1002/mpr.229

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  71 in total

Review 1.  Hepatitis C, interferon alfa, and depression.

Authors:  D Zdilar; K Franco-Bronson; N Buchler; J A Locala; Z M Younossi
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.

Authors:  Abraham Reichenberg; Jack M Gorman; Douglas T Dieterich
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

4.  Factors influencing the self-rating depression scale.

Authors:  W W Zung
Journal:  Arch Gen Psychiatry       Date:  1967-05

5.  Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors.

Authors:  Jeannette Golden; Anne Marie O'Dwyer; Ronán M Conroy
Journal:  Gen Hosp Psychiatry       Date:  2005 Nov-Dec       Impact factor: 3.238

Review 6.  Neurobehavioral effects of interferon therapy.

Authors:  Alan D Valentine; Christina A Meyers
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

7.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

8.  Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

Authors:  M R Kraus; A Schäfer; H Faller; H Csef; M Scheurlen
Journal:  Aliment Pharmacol Ther       Date:  2002-06       Impact factor: 8.171

9.  Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.

Authors:  E Jonasch; U N Kumar; G P Linette; F S Hodi; R J Soiffer; B F Ryan; A J Sober; M C Mihm; H Tsao; R G Langley; B A Cosimi; M A Gadd; K K Tanabe; W Souba; H A Haynes; R Barnhill; R Osteen; F G Haluska
Journal:  Cancer J       Date:  2000 May-Jun       Impact factor: 3.360

10.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  18 in total

1.  Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.

Authors:  Maryam Alavi; Jason Grebely; Gail V Matthews; Kathy Petoumenos; Barbara Yeung; Carolyn Day; Andrew R Lloyd; Ingrid Van Beek; John M Kaldor; Margaret Hellard; Gregory J Dore; Paul S Haber
Journal:  J Gastroenterol Hepatol       Date:  2012-05       Impact factor: 4.029

2.  Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.

Authors:  D M Evon; D E Esserman; M A Howell; R A Ruffin
Journal:  Pharmacopsychiatry       Date:  2014-08-14       Impact factor: 5.788

3.  Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.

Authors:  Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn
Journal:  Cognit Ther Res       Date:  2019-02-12

4.  Anemia management in the era of triple combination therapy for chronic HCV.

Authors:  Ira M Jacobson; Kris V Kowdley; Paul Y Kwo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09

5.  Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.

Authors:  James R Rodrigue; William Balistreri; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Steven J Lobritto; Kathleen B Schwarz; Patricia R Robuck; Bruce Barton; Regino P González-Peralta
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 6.  Neurological complications of hepatitis C infection.

Authors:  Micheline McCarthy; Melissa R Ortega
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

7.  Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.

Authors:  Benjamin J Morasco; Jennifer M Loftis; David W Indest; Samantha Ruimy; John W Davison; Bradford Felker; Peter Hauser
Journal:  Psychosomatics       Date:  2010 Sep-Oct       Impact factor: 2.386

8.  Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options.

Authors:  Carmen Denise Mihaela Zahiu; Mihai Rimbas
Journal:  Maedica (Buchar)       Date:  2014-06

Review 9.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

10.  Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

Authors:  Kimberley J Smith; Suzanne Norris; Cliona O'Farrelly; Shane M O'Mara
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.